Intellia Therapeutics (NTLA) faces heightened uncertainty after pausing patient enrollment and dosing in two Phase 3 trials of its gene-editing therapy, nex-z, BofA said Friday in a report, downgrading the company's stock and slashing its price target.

On Monday, Intellia announced it had halted trials for patients with transthyretin amyloidosis with cardiomyopathy and polyneuropathy after a participant experienced elevated liver enzymes and bilirubin levels following treatment.

Nex-z, Intellia's largest potential revenue driver, "is now delayed with a potentially more complicated path to market," BofA said, lowering its estimated probability of success for both programs.

BofA downgraded its rating on Intellia to neutral from buy and cut its price target to $14 from $30.

Shares of Intellia rose 4% in recent Friday trading. The stock plunged 42% on Monday after the corporate announcement.

Price: 12.76, Change: +0.49, Percent Change: +4.04